In B cell acute lymphoblastic leukemia (B-ALL), CD19 loss accounts for up to 75% of relapses after CAR T cell therapy [15] while approximately a third of relapses in diffuse large B cell lymphoma (DLBCL) show CD19 loss or downregulation [16]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.